Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia

Leuk Lymphoma. 2017 Jul;58(7):1764-1766. doi: 10.1080/10428194.2016.1260127. Epub 2016 Nov 28.

Authors

Ester Maria Orlandi¹, Chiara Elena^{1

2}, Elisa Bono³

Affiliations

¹ a Department of Oncology-Hematology, Hematology Unit , Fondazione IRCCS Policlinico San Matteo , Pavia , Italy.
² b Department of Molecular Medicine , University of Pavia , Pavia , Italy.
³ c Department of Oncology-Hematology , School of Hematology, University of Pavia, Hematology Unit, Fondazione IRCCS Policlinico San Matteo , Pavia , Italy.

PMID: 27892750
DOI: 10.1080/10428194.2016.1260127

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Hepatitis B / complications*
Hepatitis B / diagnosis
Hepatitis B / immunology
Hepatitis B / virology*
Hepatitis B virus / drug effects*
Hepatitis B virus / immunology
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Male
Middle Aged
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Risk Assessment
Virus Activation / drug effects*
Virus Activation / immunology
Young Adult

Substances

Antineoplastic Agents
Protein Kinase Inhibitors